JUVÉDERM®

About JUVÉDERM® — Technology, Manufacturer, and Safety

JUVÉDERM® is made by Allergan Aesthetics, an AbbVie company. AbbVie acquired Allergan in 2020, and the operating aesthetics unit still carries the Allergan name. Every JUVÉDERM® syringe is manufactured at the Allergan facility in Pringy, France, with US-market products produced to FDA manufacturing standards.

JUVÉDERM® formulations are based on cross-linked hyaluronic acid molecules designed to modify how HA behaves after injection. The gel matrix helps attract water within treated tissues while the degree of cross-linking influences cohesivity, durability, and product performance.

Cross-linking Platforms

VYCROSS® combines high-molecular-weight and low-molecular-weight HA chains in a monophasic, cohesive gel, and it underpins VOLUMA®, VOLLURE™/VOLIFT™, VOLBELLA®, VOLUX™, and VOLITE®/SKINVIVE™.

HYLACROSS™ is the older high-concentration cross-linking method behind the ULTRA family (ULTRA XC, ULTRA PLUS XC, ULTRA 3, and ULTRA 4). The “XC” suffix marks products formulated with 0.3% lidocaine for injection comfort. All US FDA-approved JUVÉDERM® fillers include lidocaine. Several EU/international SKUs are sold without lidocaine for practitioners who manage anesthesia separately.

On regulatory footing, the range is CE-marked in Europe and the XC line is FDA-approved in the US, backed by clinical trial programs across cheek, lip, fold, jawline, undereye, and skin-quality indications. These dermal fillers are HA-based, so treatment is reversible with hyaluronidase when adjustment or dissolution is clinically warranted.

Clinics that keep a wider bench often pair JUVÉDERM® with cross-brand HA dermal fillers where a non-VYCROSS® gel or a firmer NASHA®-type structure suits the indication better, and reach into the broader dermal fillers category for CaHA- or PLLA-based biostimulators when the treatment plan calls for collagen remodeling rather than direct volume. Skin-quality work runs in parallel: SKINVIVE™ and VOLITE® sit in the Skinboosters class alongside Restylane® SKINBOOSTERS™, Teosyal® REDENSITY I, and Profhilo®.

JUVÉDERM® Product Range — All Products with Clinical Detail

Below is the complete lineup of JUVÉDERM® fillers, each with the indication that drives its use, the clinical logic behind its formulation, and the administration technique.

JUVÉDERM® VOLUMA® XC

VOLUMA® XC is indicated for cheek augmentation and midface volume restoration in adults 21 and older. US labeling also covers chin augmentation and correction of moderate to severe temple hollowing in adults. Its VYCROSS® formulation produces a highly cohesive gel with a firm elastic modulus (G’), which is what delivers structural lift rather than fill. FDA data support results up to 24 months in the cheeks [1], the longest duration in the JUVÉDERM® line.

Administration is a deep injection, supraperiosteal or deep subcutaneous, in the cheek, midface, chin, or temple region as the indication warrants, delivered by needle or cannula. The XC formulation contains lidocaine.

JUVÉDERM® VOLIFT™ / JUVÉDERM® VOLLURE™ XC

VOLIFT™ is the EU/international name for the same VYCROSS® gel sold as VOLLURE™ XC in the US. It treats moderate to severe facial wrinkles and folds, including nasolabial folds, smile lines, and marionette lines.

The gel sits at a lower G’ than VOLUMA® with a balanced cohesivity, which lets it soften folds without leaving tissue over-corrected. The pivotal VYC-17.5L trial reported responder rates of 93% at 12 months, 85% at 15 months, and 59% at 18 months, which is why the practical answer for duration is “up to 18 months” rather than a flat 18-month figure [2]. Placement is mid-dermis to deep dermis along the fold line by needle or cannula. Lidocaine is included in the XC version.

JUVÉDERM® VOLBELLA® XC

VOLBELLA® XC sits at the softest, lowest-G’ end of the VYCROSS® spectrum. Its US label carries three indications: lip augmentation in adults 21 and over, correction of perioral (vertical lip) lines in the same age group, and, since 2022, improvement of the appearance of undereye hollows (infraorbital hollows) in adults over 21, with Allergan product training required before treating the undereye area.

Its formulation is what recommends it for lip work: enough cohesivity to hold shape, not enough volumizing capacity to overfill. A 12-month randomized, controlled study of lip and perioral enhancement supports the FDA-approved duration in the lips [3]. Administration is submucosal or intradermal into the lip body and vermilion border, with cannula technique often preferred in the perioral area to reduce bruising. Lidocaine is included.

JUVÉDERM® ULTRA XC / JUVÉDERM® ULTRA PLUS XC

ULTRA XC and ULTRA PLUS XC are the HYLACROSS™ workhorses of the collection and remain, together, the most-used JUVÉDERM® pair worldwide. ULTRA XC is FDA-approved for lip augmentation and moderate nasolabial folds. ULTRA PLUS XC is FDA-approved for deeper, more severe folds and wrinkles.

ULTRA XC is the everyday clinical pick for lip augmentation where cost-per-syringe matters, typically holding 9–12 months of lip duration. ULTRA PLUS XC sits deeper, in nasolabial folds and severe wrinkles. Both formulations contain lidocaine.

JUVÉDERM® VOLUX™ XC

In the VYCROSS® family, VOLUX™ XC sits at the highest G’ and is the newest addition to the JUVÉDERM® portfolio. It is the only JUVÉDERM® gel purpose-built for the lower-face structural zone. In the US, VOLUX™ XC is FDA-approved for improvement of moderate to severe loss of jawline definition in adults over 21. Chin augmentation is a common off-label use in the US market. The on-label US chin filler is VOLUMA® XC. In EU/international markets, VOLUX™ is labeled for use along the jawline, mandibular angle, and chin.

A randomized US study of VYC-25L showed maintained jawline definition through 12 months, which is the reference figure for duration [4]. Administration is deep supraperiosteal or deep subcutaneous, via blunt cannula or needle. Lidocaine is included in the XC formulation.

JUVÉDERM® VOLITE® / SKINVIVE™ by JUVÉDERM®

VOLITE® is the international name and SKINVIVE™ is the US name for the microinjection skin booster in the VYCROSS® family. It is engineered for skin quality, hydration, texture, and fine lines, not for volume. In the US, SKINVIVE™ is FDA-approved for improving cheek skin smoothness in adults 21 and over.

The gel is placed as superficial intradermal microdroplets by serial puncture or retrograde linear technique. Neck, décolletage, and hands are treated off-label. A randomized US trial of VYC-12L demonstrated improvement in cheek skin smoothness, fine lines, and hydration through 6 months, which sets the practical maintenance interval [5]. The line competes with Restylane® SKINBOOSTERS™, Teosyal® REDENSITY I, and Profhilo®. Practitioners interested in the class can browse Skinboosters.

JUVÉDERM® HYDRATE®

HYDRATE® is a legacy EU/international skin-hydration product built on non-cross-linked or lightly cross-linked HA for biorevitalization. It sits alongside VOLITE® in the skin-quality category with a different formulation profile. It has never been FDA-approved and is not sold in the US.

Administration is a microinjection technique across the face, neck, and décolletage. Availability varies by market, so confirm current distribution with AbbVie or the local distributor before quoting a client.

JUVÉDERM® VOLITE® for Lips (Off-Label Lip Hydration)

There is no dedicated VOLITE® lip SKU. VOLITE® is labeled for fine lines and skin hydration in the face, neck, décolletage, and hands. Published clinical experience, however, documents microinjection VOLITE® for lip hydration and a subtle “lip gloss” effect in patients who want smoother lip skin without added volume. On-label lip options in the JUVÉDERM® range remain VOLBELLA® and ULTRA XC.

Where an injector chooses VOLITE® off-label at the lip, the technique is superficial intradermal microdroplet by serial puncture or, preferably, cannula, which reduces bruising and intravascular risk. This is off-label use for trained, licensed injectors.

JUVÉDERM® ULTRA 3 / ULTRA 4

ULTRA 3 and ULTRA 4 are the EU/international HYLACROSS™ SKUs. ULTRA 3 matches ULTRA XC for moderate lines and lip volume, though some markets sell it without lidocaine. ULTRA 4 is the thicker gel for deeper folds and stronger volume correction, roughly comparable to ULTRA PLUS XC. Both are chosen where the XC versions are unavailable or where budget drives selection.

Placement follows viscosity. ULTRA 3 is intradermal for lips and moderate folds. ULTRA 4 is deep subcutaneous for nasolabial folds and severe wrinkles. Lidocaine content varies by market, so the specific formulation should be confirmed against the label.

JUVÉDERM® VOLUMA® (Non-XC / EU Version)

A lidocaine-free VOLUMA® is available in EU/international markets for injectors who prefer to run their own topical or nerve-block anesthesia. The gel is the same VYCROSS® formulation as VOLUMA® XC, and cheek and midface indications match the XC version.

JUVÉDERM® VOLBELLA® (Non-XC / EU Version)

The non-XC VOLBELLA® is the same low-G’ VYCROSS® gel supplied without lidocaine in EU/international markets. It covers the same lip augmentation and perioral-line indications as VOLBELLA® XC.

Treatment Areas and Key Clinical Indication

• Lips: ULTRA XC for volume, VOLBELLA® XC for a subtle, natural result and vertical perioral lines.
• Cheeks: VOLUMA® XC delivers structural, long-lasting midface support [1].
• Jawline: VOLUX™ XC is the dedicated product, with US FDA approval for improvement of moderate to severe loss of jawline definition in adults over 21 [4].
• Smile lines and folds: VOLLURE™/VOLIFT™ for moderate folds, ULTRA PLUS XC for deeper ones.
• Temple: VOLUMA® XC, on-label in the US for correction of moderate to severe temple hollowing.
• Chin: VOLUMA® XC on-label in the US, with VOLUX™ off-label for chin in the US and on-label for chin in EU markets.
• Undereye: VOLBELLA® XC, FDA-approved in the US for the appearance of undereye hollows (infraorbital hollows).
• Skin quality: SKINVIVE™/VOLITE® sits in the skinboosters category rather than the volumizing lineup [5].

JUVÉDERM® Facial Fillers Compared to Other HA Fillers

Different HA dermal filler brands use distinct formulation approaches that influence gel properties, treatment applications, and clinical performance. When evaluating JUVÉDERM® alongside other filler technologies, practitioners consider factors such as product composition, rheology, approved indications, clinical evidence, and the desired aesthetic outcome.

Rather than selecting a filler based on brand name alone, practitioners evaluate how each formulation performs in specific treatment areas. The comparisons below highlight key differences between JUVÉDERM® and other established HA filler technologies.

JUVÉDERM® vs TEOSYAL®

TEOSYAL® fillers from Teoxane are built around RHA® (Resilient Hyaluronic Acid) technology, which is designed to maintain flexibility in areas affected by facial movement. This characteristic is particularly relevant for dynamic facial regions where expression-related movement is a key consideration.

JUVÉDERM® uses VYCROSS® and HYLACROSS™ technologies to create a range of HA fillers with different levels of cohesivity and structural characteristics. Products such as VOLUMA®, VOLBELLA®, and VOLUX™ are designed for different aesthetic applications, including facial volume restoration, lip enhancement, and lower-face contouring.

For cheek augmentation, VOLUMA® has clinical data supporting correction lasting up to 24 months [1]. For other indications, product selection depends on the intended treatment area and the characteristics required from the filler.

JUVÉDERM® vs Restylane®

Restylane® and JUVÉDERM® are two widely recognized HA filler families used across aesthetic medicine. Restylane® products utilize technologies including NASHA® and XpresHAn Technology™, while JUVÉDERM® products are based on VYCROSS® and HYLACROSS™ platforms.

These technologies differ in their approach to gel structure and tissue interaction. Restylane® products such as LYFT are commonly associated with structural support, while JUVÉDERM® offers a broad portfolio covering multiple treatment areas, including cheeks, lips, folds, jawline definition, and skin quality improvement.

In cheek augmentation, JUVÉDERM® VOLUMA® has demonstrated correction lasting up to 24 months in clinical studies [1]. Both HA filler families are reversible with hyaluronidase when clinically appropriate.

JUVÉDERM® vs BELOTERO®

Merz’s BELOTERO® uses Cohesive Polydensified Matrix (CPM) technology, which is designed to create a smooth gel integration pattern within superficial tissue layers.

JUVÉDERM® approaches facial correction through multiple HA filler formulations developed for different aesthetic needs, including volume restoration, facial contouring, wrinkle correction, lip enhancement, and skin-quality treatments.

The distinction between these product families is primarily related to formulation design and intended application. Practitioners may consider treatment depth, correction goals, and product characteristics when selecting between options.

JUVÉDERM® vs SAYPHA®

Croma Pharma’s Austrian SAYPHA® is an HA filler range that includes formulations intended for different aesthetic applications, including fine lines, volume restoration, and deeper implantation.

JUVÉDERM® combines two technology platforms — VYCROSS® and HYLACROSS™ — across a portfolio designed for multiple facial indications. The range includes products for lips, cheeks, folds, jawline definition, and skin quality improvement.

When comparing HA filler options, practitioners may evaluate factors such as available indications, clinical experience, product characteristics, and regulatory approvals.

JUVÉDERM® vs REVANESSE®

Prollenium’s Canadian-made REVANESSE® is designed for applications such as facial enhancement and volume correction.

JUVÉDERM® provides a broader collection of formulations, including VOLUMA®, VOLBELLA®, VOLLURE™, VOLUX™, and VOLITE®/SKINVIVE™, covering different aesthetic treatment goals.

Selection between these filler families depends on the treatment indication, desired correction, patient characteristics, and practitioner familiarity with each product.

JUVÉDERM® vs STYLAGE®

Laboratoires VIVACY’s STYLAGE® uses IPN-Like technology and incorporates mannitol in selected formulations as part of its product design.

JUVÉDERM® products are based on VYCROSS® and HYLACROSS™ technologies, with formulations developed for applications ranging from facial volume restoration to lip enhancement, wrinkle correction, jawline contouring, and skin quality improvement.

Both filler families represent different approaches to HA technology. Practitioners typically evaluate formulation characteristics, clinical data, treatment goals, and patient needs when selecting an appropriate product.

Duration and Safety

Duration in the JUVÉDERM® range varies by product and treatment area. VOLUMA® holds up to 24 months in the cheeks [1]. VOLLURE™/VOLIFT™ correction extends up to 18 months in a majority of subjects [2]. VOLBELLA® XC delivers up to 12 months in the lips [3]. ULTRA XC typically maintains 9–12 months in the lips. VOLUX™ XC maintains jawline definition through 12 months in the randomized VYC-25L study [4]. SKINVIVE™/VOLITE® runs around six months with maintenance sessions [5]. Results become visible from around two weeks post-treatment, once initial swelling resolves, and individual response varies with metabolism, product volume, and treatment area.

On safety, the range carries CE marking and FDA approval across its main indications. The most common side effects are treatment-site reactions such as redness, swelling, pain, tenderness, and bruising, typically resolving within days. Pigmentation disorders are uncommon. The more serious risk with any HA filler is unintended intravascular injection, which can produce vascular occlusion. That risk is technique-dependent, and injection should be delivered by clinicians with strong facial anatomy knowledge and complication management training.

Where to Buy JUVÉDERM® Wholesale Online

Doctor Medica supports licensed aesthetic practices with access to authentic JUVÉDERM® products, reliable fulfillment, and ordering support for ongoing clinical needs. Every order ships through temperature-controlled logistics built for HA fillers, backed by a Price Beat program, free shipping on orders over $1,000, and a 14-day delivery guarantee that is often faster within the USA. License verification returns within 24 hours, so approved practitioners can move from account setup to their first order without a long wait.

Order JUVÉDERM® wholesale with no minimum order requirement. Every shipment goes out with LOT-verified authentic stock, volume-based wholesale savings, a dedicated account manager, and fully tracked international fulfillment, whether you want to buy JUVÉDERM® online for a single product line or buy JUVÉDERM® products across the collection. Doctor Medica’s staff handles bulk quotes and repeat orders directly. Reach out to order JUVÉDERM® online at a bulk-quote rate.

FAQs

What is JUVÉDERM®?

JUVÉDERM® is a portfolio of hyaluronic acid injectable treatments developed by Allergan Aesthetics and now marketed under AbbVie. The range includes multiple formulations designed for different aesthetic applications, including facial volume restoration, contour refinement, wrinkle correction, lip enhancement, and skin quality improvement.

What is SKINVIVE™ by JUVÉDERM®?

The US brand name for JUVÉDERM® VOLITE®, a microinjection HA skin booster FDA-approved for improving cheek skin smoothness. It is not a volumizing filler and is delivered via intradermal microinjection, with clinical trial data showing improvement through 6 months [5].

Which JUVÉDERM® is best for lips?

It depends on the goal: ULTRA XC for noticeable volume, VOLBELLA® XC for subtle enhancement and perioral lines, VOLLURE™/VOLIFT™ for the lip border and surrounding folds. The practitioner selects based on lip tissue, volume goal, and patient preference.

How long does JUVÉDERM® last?

Duration varies by product and area: VOLUMA® up to 24 months in the cheeks [1]; VOLLURE™/VOLIFT™ up to 18 months in folds [2]; VOLBELLA® XC up to 12 months in the lips [3]; ULTRA XC 9–12 months in the lips; VOLUX™ XC up to 12 months in the jawline [4]; SKINVIVE™/VOLITE® around six months [5].

Can JUVÉDERM® be removed?

Yes. Every filler in the collection is HA-based, and hyaluronidase can dissolve or adjust the gel when clinically warranted, usually within 24–72 hours. Only a trained clinician should perform reversal.

Is JUVÉDERM® safe? What are the side effects?

JUVÉDERM® is CE-marked in Europe and FDA-approved for the XC range in the US, backed by one of the largest clinical safety datasets of any HA filler brand. Common side effects (redness, swelling, pain, bruising, tenderness) are typically mild and short-lived. Vascular occlusion is the rare but serious event to plan for and is technique-dependent.

Does JUVÉDERM® have lidocaine?

All US FDA-approved JUVÉDERM® fillers contain lidocaine, and the “XC” suffix marks the 0.3% lidocaine-containing formulations. Several EU/international SKUs, including non-XC VOLUMA®, non-XC VOLBELLA®, and specific ULTRA 3/4 formulations, are sold without lidocaine.

How is JUVÉDERM® different from BOTOX®?

They are not interchangeable. JUVÉDERM® is an HA filler that adds volume, restores contour, and improves skin quality. BOTOX® is a botulinum toxin neuromodulator that softens dynamic expression lines by relaxing muscle activity. Many full-face protocols use both, since the two address different aesthetic concerns.

Where can practitioners buy JUVÉDERM® wholesale?

Doctor Medica. Licensed practitioners can buy JUVÉDERM® online with a Price Beat program, free shipping over $1,000, LOT-verified stock, 24-hour license verification, and a dedicated account manager on every order. Doctor Medica’s staff handles bulk quotes and repeat account orders.

Disclaimer: For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Citations

[1] Callan, Peter et al. “Efficacy and safety of a hyaluronic acid filler in subjects treated for correction of midface volume deficiency: a 24 month study.” Clinical, cosmetic and investigational dermatology vol. 6 81-9. 20 Mar. 2013, doi:10.2147/CCID.S40581
[2] Dayan, Steven et al. “Safety and Effectiveness of VYC-17.5L for Long-Term Correction of Nasolabial Folds.” Aesthetic surgery journal vol. 40,7 (2020): 767-777. doi:10.1093/asj/sjz200
[3] Raspaldo, Hervé et al. “Lip and Perioral Enhancement: A 12-Month Prospective, Randomized, Controlled Study.” Journal of drugs in dermatology : JDD vol. 14,12 (2015): 1444-52.
[4] Rivkin, Alexander et al. “Safe and Effective Restoration of Jawline Definition With Hyaluronic Acid Injectable Gel VYC-25L: Results From a Randomized Controlled Study.” Aesthetic surgery journal vol. 44,12 (2024): 1341-1349. doi:10.1093/asj/sjae147
[5] Alexiades, Macrene et al. “A Randomized, Multicenter, Evaluator-blind Study to Evaluate the Safety and Effectiveness of VYC-12L Treatment for Skin Quality Improvements.” Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] vol. 49,7 (2023): 682-688. doi:10.1097/DSS.0000000000003802

Written by Doctor Medica’s Editorial team

The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.

Doctor Medica sources products exclusively through authorized distributors and established procurement channels. Products are verified as genuine, and supplied in the original packaging with their seal intact. Learn more about how we guarantee product authenticity, sourcing compliance, and traceable delivery to our clients.